Aptagen, LLC
RNA
ppERK2/ERK2
Protein
4.7 nM (reported value)
Selection Buffer (10 mM HEPES (pH 7.5) and 10 mM MgCl2)
30°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
ppERK2/ERK2 (ID# 73)
5'rGprGprGprAprGprAprGprCprCprAprUprAprCprCprUprGprAprCprAprAprAprGprAprCprGprCprUprAprGprCprGprAprAprUprUprGprGprUprUprCprCprUprCprAprCprUprCprAprAprAprAprGprUprAprGprGprGprGprAprAprAprGprCprGprUprUprAprUprUprAprAprGprAprAprAprCprCprAprAprAprAprUprUprUprGprAprCprAprGprGprUprUprAprCprGprCprAprUprCprCprUprGprCprAprUprCprCprUprCprCprAprGprGprUprUprAprCprGprCprAprUprCprCp3'
123
39558.93 g/mole
1233700 L/(mole·cm)
47.15%
0.81
32.07
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Seiwert, S., et al. "RNA aptamers as pathway-specific MAP kinase inhibitors." Chemistry and Biology, 7 (2000): 833-843.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.